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immediate canthotomy and cantholysis to reduce intra-
orbital pressure. Immediate improvements in visual acuity
and papillary light responses were observed. Intravenous and
then oral acetazolamide were used to further reduce intra-
orbital pressure. Subsequent treatment included a topical
lubricant, topical chloramphenicol, and oral co-amoxiclav
for 7 days. Her visual acuity returned to baseline.
DISCUSSION
Retro-orbital hematoma is a sight-threatening condition.1
Older adults may already have established impairment of
visual acuity in one or both eyes. Further visual loss may be
catastrophic in terms of functional impairment and loss of
independence. Animal models have suggested that irrevers-
ible visual loss may occur after 100 minutes.2 The etiology
of reduced visual acuity includes direct optic nerve com-
pression, central retinal artery ischemia, and compression
of optic nerve venous drainage.3,4
The presence of ophthalmoplegia, an afferent pupillary
defect, subconjunctival hemorrhage, and proptosis should
raise suspicion of retro-orbital hematoma, especially in the
context of trauma or abnormal clotting. Canthotomy and
cantholysis are recommended as first-line treatment and
reverse the threat of visual loss.5 Canthotomy involves in-
cision of the lateral canthal tendon. Further disinsertion of
the inferior crus of the lateral canthal tendon is referred to
as cantholysis. The procedure can be performed quickly
under local anesthesia. Only a small amount of blood may
be expelled. The subsequent orbital decompression facili-
tates recovery of normal orbital circulation and restora-
tion of visual acuity. The wound is usually left to heal by
secondary intention. The use of acetazolamide may be used
as an adjunct to ‘‘medically’’ reduce intra-orbital pressure
further.6
This case highlights a complication arising from a sit-
uation familiar to all physicians caring for older adults: a
traumatic fall in an anticoagulated patient. Recognition of
retro-orbital hematoma formation is essential if irreversible
visual loss is to be avoided.
Mark Scott, MB ChB
Alexander Thomson, MRCP
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INFECTION CONTROL IN LONG-TERM CARE
FACILITIES: THE NEED FOR ENGAGEMENT
To the Editor: Recently, the Society for Healthcare
Epidemiology of America (SHEA) and the Association for
Professionals in Infection Control (APIC) published up-
dated guidelines for the prevention and control of infec-
tions in long-term care facilities (LTCFs).1 This position
paper highlights the unique challenges of developing and
implementing infection control programs in the LTCF
setting.
The guidelines briefly address Clostridium difficile
infection (CDI), a growing concern among older adults in
acute and chronic care settings. Appropriate hand
hygiene (soap and water instead of alcohol-based rubs)
and contact precautions remain the mainstay for pre-
venting CDI spread. In addition, the guidelines recom-
mend that patients with active infection should be placed
in a private room or in a shared room with another pa-
tient infected with CDI, a practice known as ‘‘cohorting.’’
The authors correctly point out that, because many
patients permanently reside at these facilities and social-
ization is a vital aspect of care, consistent gown and glove
use may not be a realistic standard, potentially leading to
emotional isolation and less contact with healthcare
providers and staff.2,3
Day-to-day clinical experience raises additional ques-
tions regarding infection control strategies in the subacute
setting. Patients discharged to subacute care are generally
transferred specifically for intensive restorative therapies to
Figure 1. Right retro-orbital hematoma with proptosis (arrow).
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improve functional status. Therapy sessions typically occur
in a common area, used by many residents throughout the
facility. Should patients diagnosed with CDI be restricted
from full participation in therapy while being treated for
CDI? If so, what is the correct threshold for lifting these
restrictionsFcompletion of a 14-day course of antimicro-
bials? resolution of diarrhea? or documentation of one,
two, or three toxin-negative stool samples? Although the
prevention of CDI transmission to other residents is critical,
delaying physical and occupational therapies for even a few
days can result in additional functional decline in already
frail patients.
Another matter of concern is the patient who develops
diarrhea, spontaneously or after initiation of antimicrobials,
and is treated empirically with metronidazole or van-
comycin despite multiple negative stool toxin studies.
Should these patients be placed in private rooms or in the
general population? Sometimes, when private rooms are
not available, such patients are placed in a room with a
patient who has documented CDI. Determining an appro-
priate isolation strategy is particularly troublesome when
there is no laboratory confirmation of the CDI diagnosis.
At times, LTCFs embrace policies with little or no sup-
porting evidence, often determined by an infection control
consultant or supervisory nursing staff. For instance, it was
recently observed that patients on a subacute service who
were on contact precautions were receiving their meals in
Styrofoam containers with plastic utensils. The rationale for
this practice was rooted in the nursing staff’s concern for the
food service personnel acting as a possible vector for CDI
transmission when delivering meal trays to residents. Iron-
ically, this practice seemed to result in greater functional
impairment and probably minimal benefit in terms of in-
fection control. Some patients were having difficulty using
the plastic utensils. This practice contributed to patients not
being able to maintain adequate oral intake, particularly
troubling given their diagnosis of CDI and the associated
decrease in nutritional reserve. Because these concerns were
raised, the infection control staff is exploring alternatives.
As the burden of CDI in older adults continues to grow,
so does the need to improve our understanding of how to
prevent transmission of this serious infection, especially in
frail elderly people. Unique understanding of the LTCF
from the front line is critical to the successful development
of evidence-based approaches that keep overall goals of
therapy in mind. We urge all clinicians caring for patients in
subacute and long-term care facilities to become more
engaged in the infection control aspects of patient care.
Denise R. Flinn, MD
Preeti N. Malani, MD
University of Michigan Health System
Ann Arbor, MI
Ann Arbor Veterans Affairs Healthcare System
Ann Arbor, MI
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CONTROVERSY IN TREATING THE OLDEST OLD
WITH HYPERTENSION: IS THE HYPERTENSION IN
THE VERY ELDERLY TRIAL THE FINAL ANSWER?
To the Editor: Hypertension is common in the oldest-old
individuals and is increasing in prevalence because of the
aging population, but whether the oldest old benefit from
antihypertensive treatment is unclear.1,2 The evidence is
conflicting. The results from the pilot study of the Hyper-
tension in the Very Elderly Trial (HYVET) suggested that
treating the oldest old with stage two hypertension (systolic
blood pressure (SBP)  160 mmHg) reduced the incidence
of stroke but increased total mortality.3 Therefore, it is
difficult for the oldest-old patients with hypertension and
their providers to make decisions on antihypertensive ther-
apy. The final results of the recently published HYVET
trial4 could resolve the ongoing conflict and uncertainty
about antihypertensive therapy in the oldest old, but mis-
interpretation of new trial results could happen, so the in-
ternal validity, effect size, and the external validity of the
HYVET trial were briefly assessed, and the interpretations
of the results are shared here with the readers of the Journal
of the American Geriatrics Society.
The purpose of HYVETwas to test whether treating the
oldest old with hypertension could reduce the risk of fatal
and nonfatal stroke. The trial4 enrolled 3,845 patients aged
80 and older (mean age 83) with SBP of 160 mmHg or
greater (mean SBP 173 mmHg) and diastolic blood pressure
(DBP) of 90 to 109 mmHg (mean DBP 91 mmHg). The trial
patients were randomized to indapamide (1.5 mg) or pla-
cebo, and perindopril (2 or 4 mg) or placebo could be added
to achieve the target blood pressure of 150/80 mmHg.
HYVET was stopped early because the results demon-
strated a statistically significant reduction in total mortality
(P 5.02),4 although the primary outcome (fatal and non-
fatal stroke) barely missed statistical significance (P 5.06).
Heart failure was significantly lower in the treatment group
(Po.001).
Although the HYVET trial meets many criteria of in-
ternal validity,5,6 its early termination could limit the inter-
nal validity of the results.7 This is especially problematic
given that the stopping criteria in HYVET were not prede-
termined.8 Interpretation of the results with this consider-
ation is particularly important here given that the results
were contrary to the results of a previous meta-analysis2
and the pilot for HYVET.3
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